ERAS
Price
$12.07
Change
+$0.83 (+7.38%)
Updated
Feb 5, 02:46 PM (EDT)
Capitalization
3.48B
42 days until earnings call
Intraday BUY SELL Signals
VRDN
Price
$29.40
Change
-$0.97 (-3.19%)
Updated
Feb 5, 04:04 PM (EDT)
Capitalization
2.9B
28 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ERAS vs VRDN

Header iconERAS vs VRDN Comparison
Open Charts ERAS vs VRDNBanner chart's image
Erasca
Price$12.07
Change+$0.83 (+7.38%)
Volume$1.41K
Capitalization3.48B
Viridian Therapeutics
Price$29.40
Change-$0.97 (-3.19%)
Volume$607
Capitalization2.9B
ERAS vs VRDN Comparison Chart in %
ERAS
Daily Signal:
Gain/Loss:
VRDN
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ERAS vs. VRDN commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Buy and VRDN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (ERAS: $11.24 vs. VRDN: $30.37)
Brand notoriety: ERAS and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 69% vs. VRDN: 91%
Market capitalization -- ERAS: $3.48B vs. VRDN: $2.9B
ERAS [@Biotechnology] is valued at $3.48B. VRDN’s [@Biotechnology] market capitalization is $2.9B. The market cap for tickers in the [@Biotechnology] industry ranges from $119.38B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 0 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • ERAS’s FA Score: 0 green, 5 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, both ERAS and VRDN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 3 TA indicator(s) are bullish while VRDN’s TA Score has 2 bullish TA indicator(s).

  • ERAS’s TA Score: 3 bullish, 5 bearish.
  • VRDN’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, ERAS is a better buy in the short-term than VRDN.

Price Growth

ERAS (@Biotechnology) experienced а +10.96% price change this week, while VRDN (@Biotechnology) price change was -9.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.81%. For the same industry, the average monthly price growth was -1.54%, and the average quarterly price growth was +30.06%.

Reported Earning Dates

ERAS is expected to report earnings on Mar 19, 2026.

VRDN is expected to report earnings on Mar 05, 2026.

Industries' Descriptions

@Biotechnology (-5.81% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($3.48B) has a higher market cap than VRDN($2.9B). ERAS YTD gains are higher at: 202.151 vs. VRDN (-2.410). ERAS has higher annual earnings (EBITDA): -131.32M vs. VRDN (-298.48M). VRDN has more cash in the bank: 491M vs. ERAS (288M). VRDN has less debt than ERAS: VRDN (21.6M) vs ERAS (48.3M). VRDN has higher revenues than ERAS: VRDN (70.8M) vs ERAS (0).
ERASVRDNERAS / VRDN
Capitalization3.48B2.9B120%
EBITDA-131.32M-298.48M44%
Gain YTD202.151-2.410-8,388%
P/E RatioN/AN/A-
Revenue070.8M-
Total Cash288M491M59%
Total Debt48.3M21.6M224%
FUNDAMENTALS RATINGS
VRDN: Fundamental Ratings
VRDN
OUTLOOK RATING
1..100
5
VALUATION
overvalued / fair valued / undervalued
1..100
51
Fair valued
PROFIT vs RISK RATING
1..100
71
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
39
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ERASVRDN
RSI
ODDS (%)
Bearish Trend 2 days ago
74%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 9 days ago
82%
Declines
ODDS (%)
Bearish Trend 11 days ago
86%
Bearish Trend 2 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
Bullish Trend 2 days ago
82%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signal:
Gain/Loss:
VRDN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JORNX20.14-0.01
-0.05%
Janus Henderson Global Select T
PAEIX17.15-0.05
-0.29%
T. Rowe Price Overseas Stock Advisor
BOPCX11.46-0.07
-0.61%
Sterling Capital Special Opps C
WBSIX35.29-0.22
-0.62%
William Blair Small Cap Growth I
DADGX20.81-0.26
-1.23%
Dunham Small Cap Growth A

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been closely correlated with TERN. These tickers have moved in lockstep 87% of the time. This A.I.-generated data suggests there is a high statistical probability that if ERAS jumps, then TERN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+6.19%
TERN - ERAS
87%
Closely correlated
-6.39%
STRO - ERAS
86%
Closely correlated
+0.40%
ACET - ERAS
85%
Closely correlated
-3.51%
GLSI - ERAS
84%
Closely correlated
-3.62%
PHGE - ERAS
82%
Closely correlated
-7.36%
More

VRDN and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRDN has been closely correlated with SYRE. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if VRDN jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRDN
1D Price
Change %
VRDN100%
-4.80%
SYRE - VRDN
70%
Closely correlated
-3.66%
KRYS - VRDN
69%
Closely correlated
-3.73%
ERAS - VRDN
68%
Closely correlated
+6.19%
NRIX - VRDN
67%
Closely correlated
-1.43%
NUVL - VRDN
66%
Closely correlated
-2.03%
More